Nestle gives up on peanut allergy treatment after sluggish sales

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

By Delilah Alvarado • Sept. 5, 2023

FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

By Jonathan Gardner • Sept. 1, 2023

Novo, continuing deal streak, buys another obesity drug startup

The acquisition of Embark Biotech, which Novo helped found, gives the company another prospect to add to its arsenal of weight-loss medicines.

By Jonathan Gardner • Aug. 30, 2023

FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.

By Jonathan Gardner • Aug. 28, 2023

Danaher to buy antibody supplier Abcam for $5.7B

The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.

By Elise Reuter • Aug. 28, 2023

Royalty Pharma buys into Ferring’s cancer treatment in first gene therapy deal

The deal, worth up to $500 million, is a bet by the drug rights dealmaker on the uncertain commercial prospects of Ferring's gene therapy Adstiladrin.

By Ned Pagliarulo • Aug. 24, 2023

Illumina faces SEC probe over Grail acquisition

The regulator has asked for documents tied to the 2021 deal as well as to the conduct and compensation of Illumina and Grail management.

By Susan Kelly • Aug. 14, 2023

Novo adds another obesity drug in $1B deal for startup Inversago

The acquisition follows a similar-sized, obesity-focused buyout by Eli Lilly last month and hands Novo a weight-loss medicine already in mid-stage testing. 

By Kristin Jensen • Aug. 10, 2023

Regeneron ups genetic medicine investment with Decibel buyout

Third Rock-founded Decibel, which has shed much of its value since a 2021 IPO, expected to run out of money within a year.

By Jonathan Gardner • Aug. 9, 2023

Ikena acquires cancer startup Pionyr after Gilead passes on buyout

The all-stock deal comes months after Gilead waived an option to buy Pionyr, and gives Ikena some needed breathing room in a tough market.

By Delilah Alvarado • Aug. 7, 2023

Agios turns to Alnylam for help with rare disease push

The biotech is acquiring rights to an RNA interference medicine Alnylam invented for a rare blood disorder, continuing a corporate makeover that began in 2020. 

By Kristin Jensen • Aug. 3, 2023

TG shares tumble following licensing deal for MS drug

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

By Jacob Bell • Aug. 1, 2023

EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing

The all-stock deal is a quiet end for the ambitious biotech, which was sold for its billion-dollar bank account after the FDA derailed its plans to develop low-cost cancer medicines.

By Ben Fidler • Aug. 1, 2023

Biogen to acquire rare disease drugmaker Reata for $7.3B

The deal is a major bet by Biogen and its new CEO Chris Viehbacher, who’s reorganized R&D, cut costs and laid off staff since becoming company head last year.

By Ned Pagliarulo • Updated July 28, 2023

AstraZeneca buys Pfizer’s early gene therapy work for up to $1B

The British pharma is deepening its investment in genetic medicine through a deal for a group of Pfizer’s gene therapy delivery tools, while the New York giant cuts back. 

By Ben Fidler • July 28, 2023

New antitrust merger guidelines could have chilling effect on healthcare deals

Regulators have historically struggled to halt complex and non-traditional tie-ups. That could change with new guidelines, as the Biden administration scrutinizes healthcare M&A, antitrust experts said.

By Rebecca Pifer • July 21, 2023

Sanofi, searching for new immune system drugs, partners with a young biotech

The deal with Recludix Pharma carries a $125 million near-term payment and specifically revolves around a “STAT6,” a protein that research suggests plays a role in some respiratory and skin disorders.

By Jacob Bell • July 20, 2023

Pfizer, Flagship join forces to hunt for 10 new drugs

The unusual research alliance involves the startup creator’s Pioneering Medicines initiative, which previously struck pacts with Novo Nordisk and the Cystic Fibrosis Foundation.

By Gwendolyn Wu • July 18, 2023

Sanofi expands research deal with gene editing startup Scribe

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

By Gwendolyn Wu • Updated July 17, 2023

Novartis buys a preclinical biotech and its RNA drug technology

For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.

By Delilah Alvarado • July 17, 2023

Lilly to buy Versanis, adding to obesity drug pipeline

The pharma will pay up to $1.9 billion to acquire the privately held biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines.

By Ned Pagliarulo • July 14, 2023

RNA editing specialist Korro to go public via reverse merger

The deal with Frequency Therapeutics is the latest biotech reverse merger as private drugmakers still face challenges going public via an IPO.

By Delilah Alvarado • July 14, 2023

Illumina hit by EU with maximum fine for Grail acquisition

The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.

By Susan Kelly • July 12, 2023

Novartis cancels BeiGene deal as questions over cancer drug target persist

The companies’ decision to end their partnership on a TIGIT-blocking drug raises new doubts over a mechanism of action that has already produced setbacks for Roche and Merck.

By Jonathan Gardner • July 11, 2023

Brii buys further into VBI therapy, expanding hepatitis B partnership

The deal comes three months after VBI cut costs and laid off staff in a restructuring meant to prioritize the two medicines Brii is interested in. 

By Delilah Alvarado • July 6, 2023